Shares of Legend Biotech Co. (NASDAQ:LEGN – Get Free Report) have been given a consensus recommendation of “Buy” by the thirteen brokerages that are presently covering the company, Marketbeat reports. Thirteen investment analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $81.78.
A number of equities analysts have recently issued reports on the company. BMO Capital Markets reissued an “outperform” rating and set a $90.00 price target on shares of Legend Biotech in a research report on Wednesday, July 3rd. Royal Bank of Canada reissued an “outperform” rating and set a $86.00 price target on shares of Legend Biotech in a research report on Friday, September 27th. Scotiabank increased their price target on Legend Biotech from $70.00 to $76.00 and gave the stock a “sector outperform” rating in a research report on Monday, August 12th. Truist Financial assumed coverage on Legend Biotech in a research report on Monday, June 17th. They set a “buy” rating and a $88.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $73.00 price target on shares of Legend Biotech in a research report on Monday, September 30th.
View Our Latest Stock Report on Legend Biotech
Institutional Investors Weigh In On Legend Biotech
Legend Biotech Stock Performance
LEGN stock opened at $49.07 on Tuesday. The company has a quick ratio of 4.78, a current ratio of 4.84 and a debt-to-equity ratio of 0.25. The business’s fifty day simple moving average is $53.12 and its two-hundred day simple moving average is $50.01. Legend Biotech has a twelve month low of $38.60 and a twelve month high of $70.78. The firm has a market cap of $8.94 billion, a price-to-earnings ratio of -37.75 and a beta of 0.10.
Legend Biotech (NASDAQ:LEGN – Get Free Report) last released its earnings results on Friday, August 9th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.49. Legend Biotech had a negative return on equity of 23.20% and a negative net margin of 62.50%. The business had revenue of $186.50 million for the quarter, compared to analyst estimates of $125.25 million. During the same quarter last year, the firm posted ($0.27) earnings per share. The business’s revenue was up 154.4% compared to the same quarter last year. Analysts predict that Legend Biotech will post -1.46 earnings per share for the current year.
Legend Biotech Company Profile
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).
Recommended Stories
- Five stocks we like better than Legend Biotech
- Pros And Cons Of Monthly Dividend Stocks
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- Quiet Period Expirations Explained
- MarketBeat Week in Review – 9/30 – 10/4
- Transportation Stocks Investing
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.